Study of the adjuvant activity of new MDP derivatives and purified saponins and their influence on HIV-1 replication in vitro

Vaccine

Volumn 15, Issue 12-13, 1997, Pages 1479-1486

  Krivorutchenko, Yuri L ^a   Andronovskaja, Irina B ^a   Hinkula, Jorma ^b   Krivoshein, Yuri S ^a   Ljungdahl Ståhle, Ewa ^b   Pertel, Sergey S ^a   Grishkovets, Vladimir I ^a   Zemlyakov, Alexander E ^a   Wahren, Britta ^b  

^a V I VERNADSKY CRIMEAN FEDERAL UNIVERSITY   (Russian Federation)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

Adjuvants; HIV 1; Muramyl dipeptide derivatives; Saponins

Indexed keywords

BETA BUTYLMURAMYL DIPEPTIDE; MURAMYL DIPEPTIDE; MURAMYL DIPEPTIDE DERIVATIVE; SAPONIN DERIVATIVE; TAUROSID 1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; MALE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS ENVELOPE; VIRUS REPLICATION;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; FEMALE; HIV-1; MALE; MICE; MICE, INBRED BALB C; SAPONINS; VIRUS REPLICATION;

EID: 0030981761     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00065-0     Document Type: Article

References (48)

1. Gupta, R.K., Relyveld, E.H., Lindblad, E.B., Bazzini, B., Ben-Efraim, S. and Cupta, C.K. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 1993, 11, 293-306.
2. Fahey, J. and Schooley, R. Status of immune-based therapies in HIV infection and AIDS. Clinical and Experimental Immunology 1992, 88, 1-5.
3. Karzon, D.T., Bolognesi, D.P. and Koff, W.C. Development of a vaccine for prevention of AIDS, a critical appraisal. Vaccine 1992, 10, 1039-1052.
4. Campbell, J.B. and Bede, J.C. Antimicrobial and immunomodulatory effects of orally-administrated saponins. European Adjuvant Group Letters 1989, 5, 2541-2544.
5. Britt, W., Fay, J., Seals, J. and Kensil, C. Formulation of immunogenic human cytomegalovirus vaccine: responses in mice. Journal of Infectious Diseases 1995, 171, 18-25.
6. Lövgren, K. The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complex. Scand. J. Immunol. 1988, 27, 241-245.
7. Coughlin, R.T., Fattom, A., Chu, C., Wite, A.C. and Winston, S. Adjuvant activity of QS-21 for experimental E. coli 018 polysaccharide vaccines. Vaccine 1995, 13, 17-21.
8. Cleland, J.L., Powell, M.F., Lim, A., Barron, L., Berman, P.W., Eastman, D.J., Nunberg, J.H., Wrin, T. and Vennari, J.C. Development of a single-shot subunit vaccine for HIV-1. AIDS Research on Human Retroviruses 1994, 10, (Suppl. 2), S21-S26.
9. Wu, J.-Y., Gardner, B.H., Murphy, C.I., Seals, J.R. and Kensil, C.R. Enhancement of antigen-specific immune response to an experimental HIV-vaccine using a purified saponin as adjuvant. Journal of Immunology 1992, 148, 1519-1525.
10. Newman, M.J., Wu, J.-Y., Coughling, R.T., Murphy, C.I., Seals, J.R., Wyand, M.S. and Kensil, C.R. Immunogenicity and toxicity testing of an experimental HIV-1 vaccine in nonhuman primates. AIDS Research on Human Retroviruses 1992, 8, 1413-1417.
11. Vries, P., Heeney, J.L., Boes, J., Dings, M.E.M., Hulskotte, E.G.J., Dubbes, R., Koornstra, W., ten Haaft, P., Åkerblom, L., Eriksson, S., Morein, B., Norley, S. and Osterhaus, A.D.M.E. Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines. Vaccine 1994, 12, 1443-1452.
12. Powell, M.F., Cleland, J.L., Eastman, D.J., Lim, A., Newman, M.J., Nunberg, J.H., Weissburg, R.P., Vennari, J.C., Wrin, T. and Berman, P.W. Immunogenicity and HIV-1 virus neutralization of MN recombinant glycoprotein 120/HIV-1 QS21 vaccine in baboons. AIDS Research on Human Retroviruses 1994, 10, (Suppl 2), S105-S108.
13. Morein, B., Villacrés Eriksson, M., Åkerblom, L., Rönnberg, B., Lövgren, K. and Sjölander, A. Mechanisms behind the immune response induced by immunostimulating complexes. AIDS Research on Human Retroviruses 1994, 10, (Suppl 2), S109-S114.
14. Girard, M., Kieng, M.P., Pinter, A., Barré-Sinnoussi, F., Nara, P., Kolbe, H., Kusumi, K., Chaput, A., Reinhart, T., Muchmore, E., Ronco, J., Kaczorek, M., Gomard, E., Gluckman, J.-C. and Fultz, P.N. Immunization of chimpanzees confers protection against challenge with human immunodefficiency virus. Proceedings of the National Academy of Sciences of the United States of America 1991, 88, 542-546.
15. Ito, M., Nakashima, H., Baba, M., Pauwels, R., De Clercq, E., Shigeta, S. and Yamamoto, N. Inhibitory effect of glycyrrhizin on the in vitro infectivity and cytopathic activity of the human immunodeficiency virus (HIV). Antiviral Research 1987, 7, 127-137.
16. Eluouz, F., Adam, A., Ciorbaru, R. and Lederer, E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochemistry and Biophysics Research Communication 1974, 59, 1317-1322.
17. 14C-labelled) in the mouse. International Journal of Immunopharmacology 1979, 1, 35.
18. Ishihara, C., Hamada, N., Yamamoto, N., Ida, J., Azuma, I. and Yamamura, Y. Effect of muramyl dipeptide and its stearyl derivatives on resistance to Sendai virus infection in mice. Vaccine 1985, 3, 370-374.
19. Ishihara, C., Ida, J., Mizukoshi, N., Yamamoto, N., Yamamoto, K., Kato, K. and Azura, I. Effect of N-acetylmuramyl-L-alanyl-D-isoglutaminyl-N-stearol-L-lysin on resistance to herpes simplex virus type 1 infection in cyclophosphamide-treated mice. Vaccine 1989, 7, 309-313.
20. Nemore, K., Yoshioka, Y., Ishida, M., Okuma, K., Oka, T., Kataoka, T., Inoue, A. and Oya, A. Development of a new type of influenza subunit vaccine made by muramyldipeptideliposome: enhancement of humoral and cellular immune responses. Vaccine 1990, 8, 503-509.
21. Tamura, M., Choon, Y., Yoshimatsu, K., Yoshida, R., Oka, T., Ohkuma, K., Arikawa, J. and Azuma, I. Effect of muramyl dipeptide derivatives as adjuvants on the induction of antibody response to recombinant hepatitis B surface antigen. Vaccine 1995, 13, 77-82.
22. Bomford, R., Stapleton, M., Winsor, S., McKnight, A. and Andronova, T. The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants. AIDS Research on Human Retroviruses 1992, 8, 1765-1771.
23. Shen, L., Mazzara, G., Disciullo, S.O., Penicali, D.L. and Letvin, N.L. Immunization with lentivirus-like particles elicits a potent SIV-specific recall cytotoxic T-lymphocyte response in rhesus monkeys. AIDS Research on Human Retroviruses 1993, 9, 129-132.
24. Bui, T., Dykers, T., Hu, S.L., Faltynek, C.R. and Ho, R.J. Effect of MTP-PE liposomes and interleukin-7 on induction of antibody and cell-mediated immune responses to a recombinant HIV-envelope protein. Journal of AIDS 1994, 7, 799-806.
25. Lachman, L.B., Shih, L.-C.N., Rao, X.-M., Hu, X., Bucana, C.D., Ullrich, S.E. and Cleland, J.L. Cytokine-containing liposomes as adjuvants for HIV subunit vaccines. AIDS Research on Human Retroviruses 1995, 11, 921-932.
26. Levi, M., Rudén, U., Birx, D., Loomis, L., Redfield, R., Lövgren, K., Åkerblom, L., Sandström, E. and Wahren, B. Effects of adjuvants and multiple antigen peptides on humoral and cellular immune responses to gp160 of HIV-1. Journal of AIDS 1993, 6, 855-864.
27. Baba, M. and Shigeta, S. Antiviral activity of glycyrrhizin against varicella-zoster virus in vitro. Antiviral Research 1987, 7, 99-107.
28. Masihi, K.N., Lange, W., Rohde-Schulz, B. and Chedid, L. Muramyl dipeptide inhibits replication of HIV in vitro. AIDS Research on Human Retroviruses 1990, 6, 393-399.
29. Sidwell, R.W., Smee, D.F., Huffman, J.H., Bailey, K.W., Warren, R.P., Burger, R.A. and Penney, C.L. Antiviral activity of an immunomodulatory lipophilic desmuramyl dipeptide analog. Antiviral Research 1995, 26, 145-159.
30. Grishkovets, V.I., Tolkacheva, N.V., Shashkov, A.S. and Chirva, V.Ya. Triterpene glycosides of Hedera taurica. X. The structure of the compounds F4, I and F from Crimean Ivy leaves. Khimiya Prirodnykh Soedinenii 1992, 6, 683-686.
31. Mercer, C., Sinay, P. and Adam, A. Total synthesis and adjuvant activity of bacterial peptidoglycan derivatives. Biochemistry and Biophysics Research Communication 1975, 66, 1316-1322.
32. Whistler, R.L. and Bemiller, J.N. (Eds) Methods in Carbohydrate Chemistry. Academic Press, New York/London, 1972, Vol. VI, p. 603.
33. Flowers, H.M. and Jeanloz, R.M. The synthesis of 2-acetamido-3-O-(D-1-carboxyethyl)-2-deoxy-α-D-glucose (N-acetylmuramic acid) and of benzyl glycoside derivatives of 2-amino-3-o-(D-1-carboxyethyl)-2-deoxy-D-glucose (Muramic acid). Journal of Organic Chemistry 1963, 28, 2983-2986.
34. Dolin, R., Graham, B.S. and Greenberg, S.B. The safety and immunogenicity of a human immuno-deficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. Annals of International Medicine 1991, 114, 119-127.
35. Redfield, R.R., Brix, D.L., Ketter, N., Tramont, E., Polonis, V., Davis, C., Brundafe, J.F., Smith, G., Johnson, S., Fowler, A., Wierzba, T., Shafferman, A., Volvovitz, F., Oster, C. and Burke, D.S. Military medical consortium for applied retroviral research. New England Journal of Medicine 1991, 324, 1733-1735.
36. Wahren, B., Bratt, G., Persson, C., Levén, B., Hinkula, J., Gilljam, G., Nordlund, S., Eriksson, L., Volvovitz, F., Broliden, P.A. and Sandström, E. Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunizations with envelope glycoprotein gp160. Journal of AIDS 1994, 7, 220-229.
37. Viscidi, R., Ellerback, E., Garrison, L., Midthun, K., Clements, M.L., Clayman, B., Fernie, B. and Smith, G. NIAID AIDS VACCINE CLINICAL TRIALS NETWORK. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassays. AIDS Research on Human Retroviruses 1990, 6, 1251-1256.
38. Vaslin, B., Clavierie, J.-M., Benveniste, O., Barre-Sinoussi, F.C. and Dormont, D. Nef and gag synthetic peptide priming of antibody responses to HIV type 1 antigens in mice and primates. AIDS Research on Human Retroviruses 1994, 10, 1241-1250.
39. Sundquist, V.-A., Albert, J., Ohlsson, E., Hinkula, J., Fenyö, E.M. and Wahren, B. Human immunodificiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics. Journal of Medical Virology 1989, 29, 170-175.
40. Azuma, I. Synthetic immunoadjuvants:application to non-specific host stimulation and potentiation of vaccine immunogenicity. Vaccine 1992, 10, 1000-1006.
41. Krueger, J.M., Walter, J., Karnovsky, M.L., Chedid, L., Choay, J.P., Lefrancier, P. and Lederer, E. Muramyl peptides: variation of somnogenic activity with structure. Journal of Experimental Medicine 1984, 159, 68-76.
42. Gould-Fogerite, S., Edghill-Smith, Y., Kheiri, M., Wang, Z., Das, K., Feketeova, M., Canki, M. and Mannino, R.J. Lipid matrix-based subunit vaccines: a structure-function approach to oral and parenteral immunization. AIDS Research on Human Retroviruses 1994, 10, (Suppl. 2), S99-103.
43. Bomford, R., Stapleton, M., Winsor, S., Beesley, J.E., Jessup, E.A., Price, K.R. and Fenwick, G.R. Adjuvanticity and ISCOM formation by structurally diverse saponins. Vaccine 1992, 10, 572-577.
44. Soltysik, S., Wu, J.-Y., Recchia, J., Weeler, D.A., Newman, M.J., Coughlin, R.T. and Kensil, C.R. Structure/function studies of OS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine 1995, 13, 1403-1410.
45. Stieneker, F., Kersten, G., van Bloois, L., Crommelin, D.J.A., Hem, S.L., Löver, J. and Kreuter, J. Comparison of 24 different adjuvants for inactivated HIV-2 split whole virus as antigen in mice. Induction of titres of binding antibodies and toxicity of the formulations. Vaccine 1995, 13, 45-53.
46. Masihi, K.N., Lange, W. and Rohde-Schulz, B. Exacerbation of human immunodeficiency virus infection in promonocytic cells by bacterial immunoadjuvants. Journal of AIDS 1990, 3, 200-205.
47. Schreck, R., Bevec, D., Dukor, P., Baeverle, P.A., Chedid, L. and Bahr, G.M. Selection of a muramyl peptide based on its lack of activation of nuclear factor kB as a potential adjuvant for AIDS vaccines. Clinical and Experimental Immunology 1992, 90, 188-193.
48. Lederman, M.M., Georges, D.L., Kusner, D.J., Mudido, P., Giam, C.-Z. and Toossi, Z. Mycobacterium tuberculosis and its purified protein derivative activate expression of the human immunodeficiency virus. Journal of AIDS 1994, 7, 727-733.